| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.7 | 0.0 |
| Profit before tax | -16.1 | -17.1 |
| Net income | -16.1 | -17.2 |
| EPS (diluted, $ a share) | $-0.26 | $-0.31 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +4500.0% |
|---|
10-Q filed with the SEC, NASDAQ: CNTB. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Connect Biopharma Holdings Ltd: key numbers
- Share price
- $0.6430Close, Nov 16
- Market cap
- $41.5M
- Shares outstanding
- 64.49MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Connect Biopharma Holdings Ltd
All →Connect Biopharma Holdings Nasdaq/NYSE Compliance Notice
Connect Biopharma received a deficiency notice from Nasdaq on November 12, 2026, because its ordinary shares closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until May 11, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for at least ten consecutive business days. The notice has no immediate effect on the listing of the company's shares, which continue to trade under the symbol 'CNTB'.
- Counterparty
- Nasdaq
- Term
- 180 days
“We believe topline results from our Phase 2 Seabreeze STAT asthma and COPD studies mark a significant inflection point in the development of rademikibart as an add-on treatment to rescue bronchodilators and systemic corticosteroids for the treatment of acute exacerbations.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
“We believe these findings support the potential of rademikibart to redefine how acute exacerbations are managed, addressing both the acute event and the 4-week high-risk period following an exacerbation, to improve patient outcomes and reduce the substantial economic burden on healthcare systems.”
Barry Quart, Pharm.D., CEO and Director of Connect Biopharma
Connect Biopharma Holdings Clinical Trial Data
Connect Biopharma announced positive topline results from its global Phase 2 study of rademikibart as an add-on treatment for acute exacerbations in adults with COPD and type 2 inflammation. The study met its primary endpoint, with rademikibart reducing the rate of treatment failure by 81% and eliminating hospital readmissions or emergency department visits for new exacerbations through Week 4. The company plans to engage with the FDA to align on a Phase 3 registrational development program.
- Earnings call
- Sep 30, 2026, 8:00 AM ET
Connect Biopharma Holdings Clinical Trial Data
Connect Biopharma announced positive topline results from its global Phase 2 study of rademikibart as an add-on treatment for acute asthma exacerbations. The study met its key secondary endpoint with a statistically significant improvement in lung function (FEV1) at Day 7, and while the primary endpoint of treatment failure reduction (66%) did not reach statistical significance due to lower-than-projected event rates, the company plans to engage with the FDA for a Phase 3 program.
- Earnings call
- Sep 15, 2026, 8:00 AM ET